Approach to a combined pharmacologic therapy of childhood hyperkinesis.
The pharmacologic management of childhood hyperkinesis with psychostimulants has repeatedly proved its efficacy. In the case of hyperkinesis with an organic background (with eviden electrocencephalographic signs), the association with different anticonvulsants is usually beneficial although at times it gives rise to exceptionally undesirable side-effects, or to a paradoxically depressant action of the psychic activity. A clinical trial was carried out in 30 children aged from 5 10 years, with 2-dimethylaminoethanol in association with a magnesium salt of dipropylacetic acid (DAP).
D002648:Child; D002675:Child, Preschool; D002986:Clinical Trials as Topic; D003642:Deanol / Q000008:administration & dosage / Q000627:therapeutic use*; D004341:Drug Evaluation; D004359:Drug Therapy, Combination; D004983:Ethanolamines / Q000627:therapeutic use*; D006801:Humans; D006948:Hyperkinesis / Q000188:drug therapy*; D014631:Valerates / Q000627:therapeutic use*; D014635:Valproic Acid / Q000008:administration & dosage / Q000627:therapeutic use*
D004983:Ethanolamines; D014631:Valerates; D003642:Deanol; D014635:Valproic Acid